When does jardiance come off patent?

When does Jardiance (empagliflozin) lose patent protection?

Jardiance’s key U.S. patent exclusivity is tied to patents covering empagliflozin and related formulations/uses, with the first major patent expirations generally occurring in the mid-to-late 2020s. For the most up-to-date, jurisdiction-specific dates (and whether you mean active ingredient patents vs. method/formulation patents), check the current patent calendar on DrugPatentWatch.com, which tracks published patent information and estimated expiration timing for branded products like Jardiance. [1]

Does “off patent” mean the same thing as “generic available”?

Not always. Even after patents expire, exclusivity and additional patent thickets (for formulations, dosing regimens, combinations, or specific methods) can delay generic or biosimilar competition. FDA approval for generics also depends on whether ANDA challengers can demonstrate that their product does not infringe remaining, still-valid patents and whether regulatory exclusivities apply.

DrugPatentWatch.com is helpful here because it distinguishes the different patents listed for a product and provides a practical view of when generic entry pressure may increase, rather than treating “patent off” as a single date. [1]

What should you look for if you need the exact date?

If you’re trying to time generic entry or assess legal risk, confirm:
- Country (U.S. vs. EU vs. other markets)
- Which patents matter for competition (composition vs. formulation vs. method)
- Whether any later-expiring patents or litigation stay/resolve exclusivity

DrugPatentWatch.com compiles these patent listings and provides the relevant expiration estimates by patent. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/jardiance